84. CES 2026 | Las Vegas

At CytoAurora Biotechnology, we have long been dedicated to the development and application of single-cell technologies, integrating semiconductor processes, precision mechanics and optical systems, AI-driven software, as well as molecular pathology and biochemistry to continuously develop high-precision medical diagnostic and optical analysis solutions.

In cancer cell image recognition and analysis, we combine advanced optical architectures with fully automated AI analysis to establish a digital imaging and analytical workflow that bridges cytopathology and histopathology, addressing clinical needs for stability, consistency, and quantifiable results.

As CES 2026 officially opens today (January 6), the Nano CAST™ Cancer Solution, integrating AI-based imaging analysis, semiconductor-guided precision optics, and specially modified antibody chemistry, has once again received recognition on this global technology stage and was named an Innovation Awards Honoree.

This milestone also signifies our continued commitment on the international stage to advancing clinically meaningful diagnostic solutions, built upon a solid and reliable technological foundation.

醫華生技長期投入單細胞技術的研發與應用，整合半導體製程、精密機械與光學系統、AI 人工智慧軟體，以及分子病理與生物化學技術，持續自主研發高精度的精準醫療檢測與光學分析設備。

在癌細胞影像辨識與分析的應用上，我們透過精密光學架構與全自動 AI 分析系統，建立同時涵蓋細胞病理與組織病理的數位影像與分析流程，回應臨床端對於穩定性、一致性與可量化結果的實際需求。

隨著 CES 2026 於今日（1/6）正式開展，今年的 Nano CAST™ Cancer Solution 結合 AI 影像分析、由半導體技術引導的精密光學設計，以及特殊化學修飾抗體，再次在這個全球指標性的科技舞台上獲得肯定，榮獲 Innovation Awards Honoree，也象徵著我們在國際舞台上，將持續以穩健的技術基礎，推動具備臨床價值的檢測解決方案向前發展。

Youtube Link : https://youtu.be/DzbSjEawZdo

#ces2026 #honoree #digitalhealth